Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MethylGene PIPE sets market alight

This article was originally published in Scrip

Executive Summary

Investors were clearly impressed with the news that MethylGene, the Canadian biopharmaceutical company, was able to raise Can$33.7 million ($34.5 million) in a private placement to institutional investors (private investment in public equity or PIPE), when it only had a market cap of $5.1 million and was effectively running on fumes. "There was clearly a disconnect between the value of our technology and where the stock was trading. We had Can$ 10 million in cash on 30 September last year and we told the market that we had cash resources to take us to the end of the first quarter," president and ceo Charles Grubsztajn told Scrip.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC012379

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel